Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Metrics to compare | ELIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELICPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.7x | −2.4x | −0.6x | |
PEG Ratio | −1.40 | −0.03 | 0.00 | |
Price/Book | 2.2x | 1.5x | 2.6x | |
Price / LTM Sales | 4.7x | 12.9x | 3.2x | |
Upside (Analyst Target) | - | 141.0% | 40.8% | |
Fair Value Upside | Unlock | 22.3% | 5.9% | Unlock |